Lantern Pharma

Lantern Pharma EPS

The Earnings per Share (EPS) of Lantern Pharma (LTRN) as of Nov 16, 2026 is -1.57 USD. In the previous year, Earnings per Share (EPS) was -1.93 USD — a change of -18.48% (higher).

EPS

-1.57USD

YoY

-18.48%

Last updated:

Earnings per Share (EPS) of Lantern Pharma is 2025 -1.57 USD. Earnings per Share (EPS) of Lantern Pharma was 2024 -1.93 USD. It decreases by -18.48% higher compared to the previous year.

The Lantern Pharma EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2022
-1,313.82 USD
Jan 1, 2023
-1.48 USD
Jan 1, 2024
-1.93 USD
Jan 1, 2025
-1.57 USD
Jan 1, 2026 (e)
-1.51 USD
Jan 1, 2027 (e)
-2.02 USD
Jan 1, 2028 (e)
-2.11 USD
Jan 1, 2029 (e)
-2.20 USD
The Lantern Pharma EPS history
YEAREPSYoY
est-2.20USD+4.27%
est-2.11USD+4.46%
est-2.02USD+33.77%
est-1.51USD-3.88%
-1.57USD-18.48%
-1.93USD+30.39%
-1.48USD-99.89%
-1,313.82USD+118,776.95%
-1.11USD+16.31%
-0.95USD+143.32%
-0.39USD+181.03%
-0.14USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lantern Pharma Stock analysis

What does Lantern Pharma do? Lantern Pharma develops drugs using artificial intelligence and genomic data, focusing on its RADR AI platform that processes over 25 billion data points to identify biomarker signatures for targeted therapies. The company's portfolio includes four compounds—LP-100, LP-300, LP-184, and LP-284—and an Antibody Drug Conjugate (ADC) program, with two drug candidates in clinical phases and two in preclinical stages. Its revenue model relies on partnerships and licensing agreements for its AI-driven oncology therapeutics, targeting pharmaceutical companies seeking to accelerate drug discovery through precision medicine approaches. The firm leverages its RADR platform to uncover genomic signatures correlated with drug response, enabling it to offer data-driven insights to partners in the pharmaceutical industry. Its pipeline features LP-100 and LP-300 in clinical development, while LP-184 and LP-284 are in preclinical stages, all developed using AI, machine learning, and genomic data. Lantern Pharma's business model centers on generating revenue through strategic collaborations with pharmaceutical firms interested in its AI-powered precision oncology solutions. Lantern Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lantern Pharma stock

Earnings per Share (EPS) of Lantern Pharma is -1.57 USD in 2025.

Earnings per Share (EPS) of Lantern Pharma changed from -1.93 USD to -1.57 USD, representing a -18.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Lantern Pharma since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Lantern Pharma

All Key Metrics — Lantern Pharma